Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions

DRUG: decitabine
DRUG: spartalizumab
DRUG: sabatolimab
DRUG: azacitidine
DRUG: venetoclax
DRUG: INQOVI (oral decitabine)

Sponsor

Novartis Pharmaceuticals